A cost-utility analysis of interventions for severe proliferative vitreoretinopathy

被引:28
作者
Brown, GC
Brown, MM
Sharma, S
Busbee, B
Landy, J
机构
[1] Ctr Evidence Based Hlth Care Econ, Flourtown, PA 19031 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Vasc Unit, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Cataract & Primary Eye Care Serv, Philadelphia, PA 19107 USA
[4] Queens Med Coll, Dept Ophthalmol, Ocular Cost Effect Hlth Policy Unit, Kingston, ON, Canada
[5] Queens Med Coll, Dept Epidemiol, Ocular Cost Effect Hlth Policy Unit, Kingston, ON, Canada
关键词
D O I
10.1016/S0002-9394(01)01423-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The purpose of this study was to report a reference case, patient preference,based, incremental, cost,utility analysis for treatments of retinal detachment associated with severe proliferative vitreoretinopathy (PVR). Design: Computer based economic model utilizing data from the Medicare health insurance system in the United States. Methods: A cost-utility analysis compared vitreoretinal surgery using expanding gases and silicone oil therapy to the natural course of retinal detachment associated with severe PVR. The model applies long-term published visual data from the Silicone Study Group, time tradeoff utility analysis, decision analysis with Markov modeling, and discounting of costs and health benefits as per the Panel on Cost-Effectiveness in Health and Medicine. The major outcome measure was in year 2000 United States dollars per quality-adjusted life-year ($/QALY) gained. Results: Vitreoretinal surgery for retinal detachment complicated by severe PVR, as compared with no treatment, resulted in a mean gain of 0.128-0.200 discounted (3% annual rate) quality,adjusted life,years per treated patient. Silicone oil ($/QALY gained of $40,252) was slightly more cost-effective than perfluoropropane (C3F8) gas ($/QALY gained of $46,926) in eyes with PVR without previous vitrectomy, whereas C3F8 gas ($/QALY gained of $46,162) was more cost,effective than silicone oil ($/QALY gained of $62,383) with previous vitrectomy and PVR. Sensitivity analysis resulted in a $/QALY gained of $13,347 when 10% of opposite eyes had a severe visual loss to $202,128 when a discount rate of 10% was utilized and opposite eyes initially had good vision. Conclusions: The incremental expense of interventions for retinal detachment associated with PVR is cost,effective when compared with other widely accepted interventional therapies across diverse medical specialties. (Am J Ophthalmol 2002;133:365-372. (C) 2002 by Elsevier Science Inc. All rights reserved.).
引用
收藏
页码:365 / 372
页数:8
相关论文
共 37 条
[1]   Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: Results of additional and long-term follow-up - Silicone study report 11 [J].
Abrams, GW ;
Azen, SP ;
McCuen, BW ;
Flynn, HW ;
Lai, MY ;
Ryan, SJ .
ARCHIVES OF OPHTHALMOLOGY, 1997, 115 (03) :335-344
[2]  
ANDERSON RN, 1999, US LIFE TABLES 1997, P1
[3]   PATIENTS PREFERENCES IN RANDOMIZED CLINICAL-TRIALS [J].
ANGELL, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1385-1387
[4]  
AZEN SP, 1992, ARCH OPHTHALMOL-CHIC, V110, P770
[5]  
AZEN SP, 1992, ARCH OPHTHALMOL-CHIC, V110, P780
[6]   Cost-effectiveness of treatment for threshold retinopathy of prematurity [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Tasman, W ;
Brown, HC .
PEDIATRICS, 1999, 104 (04) :e47
[7]  
Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
[8]   Incremental cost-effectiveness of laser therapy for choroidal neovascularization associated with histoplasmosis [J].
Brown, GC ;
Brown, MM ;
Sharma, S ;
Busbee, B ;
Brown, H .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2000, 20 (04) :331-337
[9]   Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration [J].
Brown, GC ;
Brown, MM ;
Sharma, S .
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2000, 35 (03) :127-133
[10]  
BROWN GC, 1999, T AM OPHTHAL SOC, V92, P474